CEO to participate in panel discussion, fireside chat focusing on psychedelics The company is engineering next-generation psychedelic molecules as it works to transform the mental health treatment landscape CYBN is implementing a three-pillar strategy Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is gaining recognition as a leader in … Continue reading “Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Participation in Upcoming Events Recognizes Company Expertise”
Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has announced that its wholly owned subsidiary, Adelia Therapeutics Inc., has a achieved a significant milestone. Specific milestones outlined in the Dec. 4, 2021, contribution agreement define what actions are to be taken when certain milestones are reached. When this specific milestone, … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes that Adelia Has Reached Milestone Achievement”
Meeting takes company a step closer to advancing its lead investigational candidate CYB003 into clinical development CYB003 is designed for the treatment of two significant conditions: major depressive disorder (“MDD”) and alcohol use disorder (“AUD”) CEO notes that CYB003 has the potential to achieve better patient outcomes The coming year holds significant promise for Cybin … Continue reading “Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Key Meeting with UK Regulatory Agency”
Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is marking key milestones to revolutionize mental health care. Among these, the company recently secured a grant for the first-ever psychedelic treatment clinic at Lenox Hill Hospital. The hospital is part of Northwell Health, the largest health care system in … Continue reading “NetworkNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Support Low-Cost/No-Cost Psychedelic Clinic for Underserved Communities”
USPTO notice marks important milestone in the expansion of CYBN’s intellectual property portfolio Once issued, patent may have opportunity to cover a broad range of claims Anxiety disorders are one of the most common mental illnesses in the United States Cybin (NEO: CYBN) (NYSE American: CYBN) has taken another step forward in its commitment to progressing … Continue reading “Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Milestone Notice of Allowance for Revolutionary Treatment of Anxiety Disorders”
Cybin (NYSE American: CYBN) (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently released its financial and operating report for Q2 2021, with notable company milestones and achievements highlighted. The company plans to move through the ongoing remaining preclinical studies for its CYB003 novel deuterated psilocybin analog and … Continue reading “NetworkNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Witnessing Swift Advancement in R&D Pipeline, Overall Business”
Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has provided a year-end summary of its major milestones and key catalysts from 2021 that it believes have positioned the company for a transformative 2022. “2021 was an exciting year for Cybin. We expanded our organization from five to more … Continue reading “NetworkNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Issues 2021 Year-End Summary”
Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, will be participating in two premier events: the 11th annual LifeSci Partners Annual Corporate Access Event and the H.C. Wainwright Bioconnect Conference. Cybin CEO Doug Drysdale will participate in both upcoming virtual investor events. At the LifeSci Partners event, scheduled for … Continue reading “NetworkNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation in Upcoming January Events”
Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has been awarded a Notice of Allowance from the U.S. Patent and Trademark Office (“USPTO”). The award is for CYBN’s patent application related to CYB004, an investigational deuterated psychedelic tryptamine compound developed for the potential treatment of anxiety disorders. According to the … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Notice of Allowance from U.S. Patent Office for Exclusive Anxiety Disorder Treatment”
Cybin (NYSE American: CYBN) (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently announced positive results from a preclinical study focusing on CYB003, one of its psilocybin programs. A recent article quotes CEO Doug Drysdale as saying, “Multiple academic studies have shown that psilocybin may have the potential … Continue reading “NetworkNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Developing Safer, More Effective Psilocybin Therapies for Patients”
